Why the brush has more hair than the floor.

The first sign is on the pillow. A few extra strands, easy to mistake for normal. Then the shower drain. Then a hairband that goes around the ponytail twice when it used to be tight. Most patients on a GLP-1 who experience this notice it between month two and month four, and the people they ask about it tend to say one of two things. The first is that the medication is not doing it. The second is that, if it is, it will pass.

Both answers are correct in the way the literature is correct. They are also too brief to be useful. The biology of what is happening, why it is happening, and what to do about it is more specific than either reply suggests.

What is actually going on

Hair grows in cycles. Each follicle on the scalp spends most of its time in a long growth phase called anagen, then a brief shedding phase called telogen, then it pushes the old hair out and starts again. In a healthy adult scalp, only about ten to fifteen percent of follicles are in telogen at any one time.¹ The rest are quietly growing.

When the body experiences a sudden stressor, a high fever, a major surgery, a fast weight loss, the loss of estrogen at menopause, a substantial share of the anagen follicles get pushed into telogen at the same time. The shedding does not show up immediately. It shows up two to four months later, when those follicles complete their telogen cycle and the hair falls out. This is called telogen effluvium, and it is the single most common cause of diffuse hair shedding in adults.²

A rapid weight loss is a textbook trigger.³ So is a sustained caloric deficit. So is an iron or zinc or protein insufficiency. So is the hormonal turbulence of menopause. A woman in her early fifties who begins a GLP-1 may be running into all four at once.

What the GLP-1 trials actually report

In the Phase 3 trials of semaglutide for obesity, alopecia (the technical term for hair thinning or loss) was reported in around three percent of patients on the active drug versus a lower rate in placebo. With tirzepatide, the reported rate is similar.⁴ Real-world rates, in patient registries and dermatology referrals, run higher. A survey of GLP-1 users published in 2024 found that nearly half reported some degree of shedding, with a smaller subset describing it as significant.⁵

The mismatch between the trial figures and the patient figures is partly definitional. Trials capture only what is reported and recorded by clinicians during a structured visit. Surveys capture what patients notice every morning in the bathroom. The two will never agree exactly.

What both sources agree on is the timeline. Shedding typically begins two to four months after weight loss begins, peaks somewhere around month six, and slows by month nine. Regrowth, in most patients, follows. The follicle is not destroyed. It is on a different schedule.

The bariatric-surgery analog

The closest published analog for what is happening with GLP-1s is bariatric surgery, where rapid weight loss has been studied for decades. Hair loss is reported by roughly half of bariatric patients, usually beginning at month three, peaking at month six, and resolving by month twelve.⁶ The biggest predictors are how fast the weight comes off, how low the calorie intake stays during the loss, and how complete the patient's intake of protein, iron, zinc, and vitamin D is during the same window.

The lessons from bariatric medicine translate directly. Patients who lose weight more slowly shed less. Patients who hit protein and micronutrient targets during the deficit shed less. Patients whose iron or thyroid function quietly drifts during the loss shed more. None of these levers stops shedding on its own. Combined, they shorten and soften it.

The follicle is not destroyed. It is on a different schedule, and the schedule can be influenced.

What the evidence supports

Three categories of intervention have actual published support for telogen effluvium and related diffuse shedding.

Topical minoxidil is the only topical with strong evidence for accelerating regrowth in this context. Daily five-percent foam or solution, applied to the scalp, has been shown in randomized trials to shorten the time to visible regrowth and to increase hair density at six months.⁷ Minoxidil is FDA-approved for androgenetic alopecia rather than telogen effluvium specifically, but the dermatology consensus is that it accelerates anagen re-entry across both.

Nutritional support is supported for patients with measurable deficiencies. Iron and ferritin levels, vitamin D, zinc, and overall protein intake are the four most-studied. A serum ferritin below 70 ng/mL has been associated with delayed regrowth in patients with telogen effluvium, and correcting low iron has been shown to improve outcomes in those patients.⁸ Routine supplementation in patients with normal levels has not been shown to help, and high-dose iron in patients with normal iron can harm.

Time is the largest single factor. The most consistent finding in the telogen effluvium literature is that, in the absence of an ongoing trigger, the hair returns. The shedding feels open-ended in month four. By month nine, in most patients, it has begun to slow and recover.⁹

What the evidence does not support is any topical that promises to stop the shed or any oral supplement that promises to thicken hair in patients without a specific deficiency. The category is full of confident packaging. The evidence is narrower than the packaging suggests.

Where this leaves a patient

A reasonable plan, for a patient on a GLP-1 who is noticing the shed, has four parts. First, a blood panel that includes ferritin, vitamin D, thyroid function, and a complete metabolic profile. The shedding may not be only from the medication. Second, a deliberate effort to hit protein and micronutrient targets during the active weight-loss window. Third, a discussion with a prescriber about whether topical minoxidil is appropriate. Fourth, patience, which is the least satisfying recommendation and the one most consistently supported by the literature.

APLOMB Roots is built around the second and third of those, with the kind of micronutrient profile the bariatric literature has identified as load-bearing during rapid weight loss. It is not a substitute for minoxidil in patients for whom minoxidil is appropriate. It is not a substitute for a ferritin test. It is what a patient who has done those things can layer on top of them.

Hair Loss on GLP-1 Medications: a practical guide to what helps

GLP-1 Side Effects: all five, and what helps

Editorial content. Not medical advice. The findings described above come from published clinical trials, dermatology reviews, and the bariatric-surgery literature; individual response varies. Talk to your prescriber or a dermatologist before starting or changing any treatment, including topical minoxidil or nutritional supplementation.